XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cancer Channel
subscribe to Cancer newsletter

Latest Research : Cancer

   DISCUSS   |   EMAIL   |   PRINT
Causes that initiate natural killer cells' specific toxic response to tumors or viruses
Apr 3, 2006, 07:24, Reviewed by: Dr. Priya Saxena

"Because NK cells can communicate different messages -- one that serves health by clearing tumors and viruses and one that serves disease by blocking the response to cancer -- understanding which signals result in effective tumor clearance is a high priority for those of us fighting cancer,"

 
Mayo Clinic researchers have identified and characterized an important signal used by the human immune system to help destroy tumors. When this signal is generated inside cells called natural killer (NK) cells, materials are released in the body that induce cell death in cancer cells. Now that this signal has been identified, new strategies can be generated for enhancing the ability of the immune system to kill tumor cells in patients with cancer.

Their report appears in the April 2 online edition of Nature Immunology (http://www.nature.com/natureimmunology). The Mayo Clinic team describes findings on causes that initiate natural killer cells' specific toxic response to tumors or viruses.

Significance of the Mayo Clinic Research

The Mayo Clinic group identified a new signaling mechanism by which natural killer cells initiate a toxic response against cancers and viruses -- an important piece of information when designing therapies that stop, reverse or protect against cancer. Natural killer cells are blood cells that have an innate ability to kill tumor cells and virus-infected cells. For example, when an NK cell encounters a new tumor developing, it may generate signals that will kill the tumor and clear it from the body. However, depending on the signals it receives, it may also communicate the opposite message -- and promote disease -- by generating signals that block the destruction of tumors or viruses.

While scientists have known that NK cells play key roles in fighting cancer, no one has known precisely how the NK cells initiate these varied tasks. The Mayo Clinic work clarifies this by identifying the biochemical players and their role in activating the toxic response against tumor cells and viruses. The Mayo Clinic team discovered a multistep process in which the proteins DAP10, PI-3K and Grb2 must interact with a structure on NK cells called NKG2D. Once that happens, NKG2D can initiate a toxic anticancer response.

"Because NK cells can communicate different messages -- one that serves health by clearing tumors and viruses and one that serves disease by blocking the response to cancer -- understanding which signals result in effective tumor clearance is a high priority for those of us fighting cancer," explains Paul Leibson, M.D., Ph.D., the Mayo Clinic immunologist and pediatrician who led the study.
 

- April 2 online edition of Nature Immunology
 

www.nature.com/natureimmunology

 
Subscribe to Cancer Newsletter
E-mail Address:

 

Together with Dr. Leibson, the work was spearheaded by M.D.-Ph.D. student Jadee Upshaw. The Mayo research team also included Laura Arneson, Renee Schoon, Christopher Dick and Daniel Billadeau, Ph.D. Their work was funded by Mayo Clinic and the National Institutes of Health.

Related Cancer News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
Breast cancer chemotherapy may deterioration in cognitive function
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Genomic signatures to guide the use of chemotherapeutics
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Listening to the sound of skin cancer
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
CDK2/FOXO1 as drug target to Prevent Tumors
Key to lung cancer chemotherapy resistance revealed


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us